Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BY-NC-NDJTO clinical and research reports

Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study

  • Jinyong Kim1
  • Sehhoon Park1
  • Gyeong-Won Lee2
  • Il-Hwan Kim3
  • Dong-Wan Kim4
  • Yun-Gyoo Lee5
  • Jang Ho Cho6
  • Eun-Kyung Cho6
  • Hyun Woo Lee7
  • Ji-Hyun Park8
  • Eun Joo Kang9
  • Youngjoo Lee10
7 more authors
  • Nak-Hoon Son11
  • So Hyeon Gwon11
  • Hyun Ae Jung1
  • Jong-Mu Sun1
  • Se-Hoon Lee1
  • Jin Seok Ahn1
  • Myung-Ju Ahn1
11 affiliations
  1. 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  2. 2Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Institute of Medical Science, Gyeongsang National University College of Medicine, Jinju, Republic of Korea
  3. 3Department of Internal Medicine, Division of Hemato-Oncology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
  4. 4Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
  5. 5Division of Hematology & Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  6. 6Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
  7. 7Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea
  8. 8Department of Hemato-oncololgy, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea
  9. 9Division of Hematology-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea
  10. 10Division of Hematology-Oncology, Department of Medicine, National Cancer Center, Goyang, Republic of Korea
  11. 11Department of Statistics, Keimyung University, Daegu, Republic of Korea
Read full textPDFCite

Related

  1. Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
    Ya Gao, Ming Liu, Lun Li +3
    The Cochrane Database of Systematic ReviewsPeer-reviewedLicence not statedFull textGeneral medicinePMC
  2. 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
    Adil Alaoui, Jessica A Catterson, Michael B Atkins +4
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Hepatic arterial infusion chemotherapy in combination with immune checkpoint inhibitors and targeted therapy for advanced intrahepatic cholangiocarcinoma.
    Li Zhang, Chengfeng Liu, Juan Zhang +6
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  4. Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
    Nolan Holley, Syed Ahmad, Gary Monroe +4
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  5. Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes
    Eleonora Camilleri, Nikola Vladic, Cornelia Englisch +10
    Research and Practice in Thrombosis and HaemostasisPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{kim2026realworld,
  title = {{Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study}},
  author = {Jinyong Kim and Sehhoon Park and Gyeong-Won Lee and Il-Hwan Kim and Dong-Wan Kim and Yun-Gyoo Lee and Jang Ho Cho and Eun-Kyung Cho and Hyun Woo Lee and Ji-Hyun Park and Eun Joo Kang and Youngjoo Lee and Nak-Hoon Son and So Hyeon Gwon and Hyun Ae Jung and Jong-Mu Sun and Se-Hoon Lee and Jin Seok Ahn and Myung-Ju Ahn},
  journal = {JTO clinical and research reports},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13718642},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
AU  - Jinyong Kim
AU  - Sehhoon Park
AU  - Gyeong-Won Lee
AU  - Il-Hwan Kim
AU  - Dong-Wan Kim
AU  - Yun-Gyoo Lee
AU  - Jang Ho Cho
AU  - Eun-Kyung Cho
AU  - Hyun Woo Lee
AU  - Ji-Hyun Park
AU  - Eun Joo Kang
AU  - Youngjoo Lee
AU  - Nak-Hoon Son
AU  - So Hyeon Gwon
AU  - Hyun Ae Jung
AU  - Jong-Mu Sun
AU  - Se-Hoon Lee
AU  - Jin Seok Ahn
AU  - Myung-Ju Ahn
PY  - 2026
DA  - 2026/08/21
JO  - JTO clinical and research reports
UR  - https://europepmc.org/article/PMC/PMC13718642
SN  - 2666-3643
ER  -